NuCana PLC ADR NCNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.17
- Day Range
- $0.95–1.22
- 52-Week Range
- $0.95–7.22
- Bid/Ask
- $1.09 / $1.10
- Shares Outstanding
- 4.16M
- Market Cap
- $4.58M
- Volume/Avg
- 283,749 / 121,328
Key Statistics
- Price/Earnings (Normalized)
- 1.22
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 12
- Website
- https://www.nucana.com
Valuation
|
Metric
|
NCNA
|
|---|---|
Price/Earnings (Normalized) | 1.22 |
Price/Book Value | 0.18 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NCNA
Financial Strength
|
Metric
|
NCNA
|
|---|---|
Quick Ratio | 4.73 |
Current Ratio | 4.73 |
Interest Coverage | −565.35 |
Quick Ratio
NCNA
Profitability
|
Metric
|
NCNA
|
|---|---|
Return on Assets (Normalized) | −25.84% |
Return on Equity (Normalized) | −33.94% |
Return on Invested Capital (Normalized) | −34.76% |
Return on Assets
NCNA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|<&%%f^ | LOCK|%>S$ | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|$%z@x< | LOCK|K?x# | $76B | |||
| Moderna Inc
MRNA
| LOCK|B><<@^V | LOCK|SVC | $75B | |||
| argenx SE ADR
ARGX
| LOCK|zlF@M< | LOCK|j< | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|y%DW<&H | LOCK|<@& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|@P!l^Z | LOCK|xX@>g | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|$XwF#$< | LOCK|<@t# | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|V&mfk?^ | LOCK|#T | $24B | |||
| Incyte Corp
INCY
| LOCK|M&Q?%>h | LOCK|&%n | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|np#!!n | LOCK|jJJ | $15B |
United States